US 9694071
Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
granted A61KA61K31/519A61K39/3955
Quick answer
US patent 9694071 (Combination of anti-CD20 antibody and PI3 kinase selective inhibitor) held by TG Therapeutics, Inc. expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TG Therapeutics, Inc.
- Grant date
- Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/519, A61K39/3955, A61K45/06, A61P